C225

C225

A chimeric IgG antibody with a strong binding affinity for epidermal growth factor (EGF) receptor, which blocks ligand—EGF, TGF α, etc.—binding and inhibits cell proliferation. C225 made it through to Phase III trials, during which time it was renamed cetuximab (Erbitux), and has proved to be a blockbuster cancer drug for head and neck cancer, colorectal and other cancers.
References in periodicals archive ?
Cetuximab (C225), a chimeric human-mouse anti-epidermal growth factor receptor (EGFR) monoclonal antibody, can improve clinical outcomes in some patients with metastatic colon cancer expressing wild type KRAS.
In vitro and in vivo experiments have confirmed the radiosensitisation of cetuximab (C225) in head and neck tumours [8].
For example [sup.99m]-Tc-EC cetuximab (C225) or [sup.89]Zr-cetuximab showed a rather high uptake in liver as well as uneven distribution within the patient without an evident specific uptake of the tracer within the tumor [33, 34].
The protein construct for cetuximab consists of Immunoglobulin G1, anti-human epidermal growth factor receptor (human-mouse monoclonal C225 g1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer [4].
Wang, "Combined effects of C225 and 125-iodine seed radiation on colorectal cancer cells," Radiation Oncology, vol.
Pole Positions for the C1, C2 and C225 categories were determined by a draw organised by race officials in the pit area.
[12.] Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
Harari, "Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck," Cancer Research, vol.
Paclitaxelenhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
The chimeric monoclonal antibody Cetuximab (C225) blocks EGFR signaling, which prompted its use in combination with radiation.
(4) A curette a fleurs in the Wallace Collection, London (C225), has a firing crack disguised by expensive gilding and repeated on the opposite lip despite the fact it would not have been visible once filled with flowers.
Earlier summaries of in vivo studies on HiFi colon adenocarcinomas, at the Sloan Kettering Cancer Center of New York, report that these tumor cells display the features of apoptosis following exposure to the anti-EGFr humanto-murine chimeric MAb C225 (13).